Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report – Forecast to 2023

Report / Search Code: MRFR/Pharma/4951-HCR  Publish Date: December, 2019

Description:

Global Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report, by Route of Administration (Intravenous Infusion), Application (Fungal Infections, Cut-Burn Wounds), End-User (Hospital, Clinics, Surgical Centre) – Global Forecast Till 2023

Market Scenario

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor and immune modulator, which is also known as colony stimulating factor 2. GM-CSF is produced by macrophages, T cells, endothelial cells, and fibroblasts. It promotes neutrophil maturation and proliferation. Neutrophils are the type of white blood cells important part of the innate immune system. It is used as a supporting agent in cancer treatment increases the immunity in a cancer patient, use after bone marrow transplantation to stimulate white blood cell proliferation, also use in dendritic cell vaccines. The key factor responsible for influencing this market is the increasing prevalence of cancer, fungal infection, unsuccessful skin grafting resolution. According to the World Health Organization (WHO), in 2015, cancer was the second leading cause of death which can support the GM-CSF market growth. However, factors such as the high cost of chemotherapy treatments, and side effects associated with the drug are expected to restrict the market growth during the forecast period.

Segmentation

The global granulocyte-macrophage-colony-stimulating factor market is segmented on the basis of route of administration, application, and end-user. The granulocyte-macrophage-colony-stimulating factor market, by route of administration, is sub-segmented into subcutaneous bolus and intravenous infusion. The granulocyte-macrophage-colony-stimulating factor market on the bases of application it is segmented into fungal infections, skin-graft, cut-burn wounds, acute myelogenous leukemia and other. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, research centers, and others. On the basis of region, the global granulocyte-macrophage-colony-stimulating factor market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players in the global granulocyte-macrophage-colony-stimulating factor market are Xconomy, Inc., Partner Therapeutics (PTx), Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA and others.

Regional Market Summary

Global Granulocyte-Macrophage Colony-Stimulating Factor Market Share (%), by Region,
Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health

It is estimated that North America dominated the global granulocyte-macrophage-colony-stimulating factor market owing to the increasing innovations in cancer research, clinical practice and access to cancer treatment in this region. National Cancer Institute (NCI) April 2018, article states that 1,735,350 new cases of cancer will be diagnosed in the United States in 2018. This influences the market growth in this region.

Europe stood second largest in the granulocyte-macrophage-colony-stimulating factor market owing to the increasing use of blood and bone marrow transplantation to treat blood diseases, cancer treatment, and immune disorders. According to the National Center for Biotechnology Information (NCBI) article 2016, that there were more than 40,000 hematopoietic stem cell transplantation in Europe in 2014. It also included Eastern European countries has shown growth in transplant activities. Such growth and a high number of transplantations in this region facilitate the market growth.

Asia-Pacific was projected to be the fastest growing region for the global granulocyte-macrophage-colony-stimulating factor market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of pharynx cancer and oral cavity in 2017 in Japan. Such a high incidence of cancer favors the market growth in this region.

The Middle East and Africa holds the least share of the global granulocyte-macrophage-colony-stimulating factor market due to the presence of poor health expenditure, low income, and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

Market Segmentation and Key Market Players

Xconomy, Inc., Partner Therapeutics (PTx), Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA, and others.

Global Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration

- Subcutaneous Bolus
- Intravenous Infusion

Global Granulocyte-Macrophage Colony-Stimulating Factor Market, by Applications

- Fungal Infections
- Skin-Graft
- Cut-Burn Wounds
- Acute Myelogenous Leukemia
- Other
Global Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-Users

- Hospitals and clinics
- Surgical centers
- Diagnostic centers
- Research centers
- Others

Global Granulocyte-Macrophage Colony-Stimulating Factor Market, by Region

- Americas
- Europe
- Asia-Pacific
- Middle East & Africa

Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Government and private laboratories
- Research and Development (R&D) companies
- Medical research laboratories
- Market research and consulting service providers

Contents:

<table>
<thead>
<tr>
<th>Chapters</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>TABLE OF CONTENT</td>
<td></td>
</tr>
<tr>
<td>Chapter 1. Report Prologue</td>
<td></td>
</tr>
<tr>
<td>Chapter 2. Market Introduction</td>
<td></td>
</tr>
<tr>
<td>2.1 Definition</td>
<td></td>
</tr>
<tr>
<td>2.2 Scope of the Study</td>
<td></td>
</tr>
<tr>
<td>2.2.1 Research Objective</td>
<td></td>
</tr>
<tr>
<td>2.2.2 Assumptions</td>
<td></td>
</tr>
<tr>
<td>2.2.3 Limitations</td>
<td></td>
</tr>
<tr>
<td>Chapter 3. Research Methodology</td>
<td></td>
</tr>
<tr>
<td>3.1 Introduction</td>
<td></td>
</tr>
<tr>
<td>3.2 Primary Research</td>
<td></td>
</tr>
<tr>
<td>3.3 Secondary Research</td>
<td></td>
</tr>
<tr>
<td>3.4 Market Size Estimation</td>
<td></td>
</tr>
<tr>
<td>Chapter 4. Market Dynamics</td>
<td></td>
</tr>
<tr>
<td>4.1 Drivers</td>
<td></td>
</tr>
<tr>
<td>4.2 Restraints</td>
<td></td>
</tr>
<tr>
<td>4.3 Opportunities</td>
<td></td>
</tr>
<tr>
<td>4.4 Challenges</td>
<td></td>
</tr>
<tr>
<td>4.5 Macroeconomic Indicators</td>
<td></td>
</tr>
<tr>
<td>4.6 Technology Trends &amp; Assessment</td>
<td></td>
</tr>
<tr>
<td>Chapter 5. Market Factor Analysis</td>
<td></td>
</tr>
<tr>
<td>5.1 Porter’s Five Forces Analysis</td>
<td></td>
</tr>
<tr>
<td>5.1.1 Bargaining Power of Suppliers</td>
<td></td>
</tr>
<tr>
<td>5.1.2 Bargaining Power of Buyers</td>
<td></td>
</tr>
<tr>
<td>5.1.3 Threat of New Entrants</td>
<td></td>
</tr>
<tr>
<td>5.1.4 Threat of Substitutes</td>
<td></td>
</tr>
<tr>
<td>5.1.5 Intensity of Rivalry</td>
<td></td>
</tr>
<tr>
<td>5.2 Value Chain Analysis</td>
<td></td>
</tr>
<tr>
<td>5.3 Investment Feasibility Analysis</td>
<td></td>
</tr>
</tbody>
</table>
Chapter 6. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Route of Administration

6.1 Introduction
6.2 Subcutaneous Bolus
6.3 Intravenous Infusion

Chapter 7. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Application

7.1 Introduction
7.2 Fungal Infections
7.3 Skin-Graft
7.4 Cut-Burn Wounds
7.5 Acute Myelogenous Leukemia
7.6 Other

Chapter 8. Global Granulocyte-Macrophage Colony-Stimulating Factor, by End-Users

8.1 Introduction
8.2 Hospitals and Clinics
8.3 Surgical Centers
8.4 Diagnostic Centers
8.5 Research Centers
8.6 Others

Chapter 9. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Region

9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
Chapter 10. Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Xconomy, Inc
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 Partner Therapeutics (PTx),
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Sanofi-Aventis U.S. LLC
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Thermo Fisher Scientific
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Merck KGaA
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Granulocyte-Macrophage Colony-Stimulating Factor Industry Synopsis, 2018–2023
Table 2 Global Granulocyte-Macrophage Colony-Stimulating Factor Estimates & Forecast, 2018–2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for the Global Granulocyte-Macrophage Colony-Stimulating Factor
Figure 3 Market Dynamics for the Global Granulocyte-Macrophage Colony-Stimulating Factor
Figure 4 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Route of Administration 2017
Figure 6 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Application, 2017
Figure 6 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by End-User, 2017
Figure 7 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Region, 2017
Figure 8 North America Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2017
Figure 9 Europe Prescribed Health Apps Share, by Country, 2017
Figure 10 Asia-Pacific Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2017
Figure 11 Middle East & Africa Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2017
Figure 12 Global Granulocyte-Macrophage Colony-Stimulating Factor: Company Share Analysis, 2017 (%)
Figure 13 Xconomy, Inc: Key Financials
Figure 14 Xconomy, Inc: Segmental Revenue
Figure 15 Xconomy, Inc: Geographical Revenue
Figure 16 Partner Therapeutics (PTx): Key Financials
Figure 17 Partner Therapeutics (PTx): Segmental Revenue
Figure 18 Partner Therapeutics (PTx): Geographical Revenue
Figure 19 Sanofi-Aventis U.S. LLC: Key Financials
Figure 20 Sanofi-Aventis U.S. LLC: Segmental Revenue
Figure 21 Sanofi-Aventis U.S. LLC: Geographical Revenue
Figure 22 Novartis AG: Key Financials
Figure 23 Novartis AG: Segmental Revenue
Figure 24 Novartis AG: Geographical Revenue
Figure 25 Thermo Fisher Scientific: Key Financials
Figure 26 Thermo Fisher Scientific: Segmental Revenue
Figure 27 Thermo Fisher Scientific: Geographical Revenue
Figure 28 Merck KGaA: Key Financials
Figure 29 Merck KGaA: Segmental Revenue
Figure 30 Merck KGaA: Geographical Revenue